INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIAL
- 1 August 2001
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 166 (2) , 476-481
- https://doi.org/10.1016/s0022-5347(05)65966-6
Abstract
After transurethral resection, we compared the efficacy and side effects of weekly intravesical instillations of epirubicin, bacillus Calmette-Guerin (BCG), and BCG plus isoniazid during a 6-week interval followed by 3 weekly maintenance instillations at months 3, 6, 12, 18, 24, 30 and 36 in patients with intermediate and high risk Ta, T1 bladder cancer. A total of 957 patients were randomized at 44 institutions in a phase III multicenter trial. The time to first recurrence was significantly longer in patients treated with BCG and BCG plus isoniazid compared to epirubicin (p = 0.0001) but there was no difference between the 2 BCG regimens (p = 0.27). Progression to muscle invasive cancer was rare (5%) and did not differ significantly among the 3 arms (p = 0.12). Drug induced cystitis was observed in 31% of the patients treated with epirubicin, 42% BCG and 45% BCG plus isoniazid. Systemic side effects, such as fever and malaise, were not observed in patients treated with epirubicin, but were noted in 31% BCG and 36% BCG plus isoniazid. Intravesical BCG with or without isoniazid provokes more side effects than epirubicin. Prophylactic isoniazid does not reduce the side effects of BCG, while BCG with or without isoniazid prolongs the time to first recurrence compared to epirubicin. Further followup is required before long-term conclusions can be made for progression-to-muscle invasive disease and survival.Keywords
This publication has 16 references indexed in Scilit:
- MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDYJournal of Urology, 2000
- Significance of Bladder Biopsies in Ta,T1 Bladder Tumors: A Report from the EORTC Genito-Urinary Tract Cancer Cooperative GroupEuropean Urology, 1999
- Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille calmette-guérin–RIVM and mitomycin c in superficial bladder cancerUrology, 1998
- Does Isoniazid Reduce Side Effects of Intravesical Bacillus Calmette-Guerin Therapy in Superficial Bladder Cancer? Interim Results of European Organization for Research and Treatment of Cancer Protocol 30911Journal of Urology, 1997
- INTRAVESICAL CHEMOTHERAPY AND IMMUNOTHERAPY: HOW DO WE ASSESS THEIR EFFECTIVENESS AND WHAT ARE THEIR LIMITATIONS AND USES?International Journal of Urology, 1995
- Improving the Efficacy of BCG Immunotherapy by Dose ReductionEuropean Urology, 1995
- A Prospective European Organization for Research and Treatment of Cancer Genitourinary Group Randomized Trial Comparing Transurethral Resection Followed by a Single Intravesical Instillation of Epirubicin or Water in Single Stage Ta, T1 Papillary Carcinoma of the BladderJournal of Urology, 1993
- Incidence and Treatment of Complications of Bacillus Calmette-Guerin Intravesical Therapy in Superficial Bladder CancerJournal of Urology, 1992
- A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the BladderNew England Journal of Medicine, 1991
- Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)BMJ, 1988